Mission Therapeutics’ Post

There is still time to register for our upcoming rare disease webinar on February 27th! Advances in the understanding of rare disease biology, coupled with innovative technology and therapeutic platforms, have led to progress in the research and development of drugs for rare diseases. Despite these advances, many rare diseases still lack useful treatments and the need for new approaches remains high. In this webinar, we will discuss important trends in rare disease therapeutics and highlight ways of accelerating the drug discovery and development process. Don’t miss your chance to ask questions to our experts! Register Now by Clicking ⬇️ https://lnkd.in/eFDFddVw #RareDiseases #RareDiseaseDay #drugdiscovery #biotech #RareDiseaseDay2024

Introducing Hornet Therapeutics: Pioneering Treatment for EBV-Driven Diseases 🚀 Exciting news for Hornet Therapeutics, as they emerge from stealth mode with groundbreaking data published in Science! 📰 This marks a significant milestone in the fight against Epstein-Barr Virus (EBV) and its related diseases. 🔑Key Highlights🔑 🐝 Revolutionary Treatment: First-ever small molecule drug for EBV-driven diseases. 🐝 Published Data: Demonstrates decreased EBV latency with IDO-1 inhibition. 🐝 Strategic Partnership: Collaboration with Kyowa Kirin. 🐝 Clinical Trials Ahead: Proof-of-concept studies for EBV-driven PTLD in transplant patients. 🌟 What Makes the Lead Asset (HTX-201) & This Antiviral Approach Significant? 🌟 👉 Addresses a significant unmet need in solid organ transplant populations. 👉 Broad Potential: Future targets include Multiple Sclerosis, Mononucleosis, and long-COVID. #Biotech #MedicalInnovation #EBV #HealthTech #Science #Transplantation #MS #LongCOVID #AntiviralTherapy #Healthcare

On this Word Lupus Awareness Day, Biomedcode is proud to contribute in the preclinical development of novel lupus-targeting human therapeutics with our recently published humanized IL23A driven mouse model of #SLE (https://lnkd.in/dH_S2PSG), a valuable disease model for studying the aetiopathogenic role of human IL23A in SLE and for validating the #preclinical in vivo #efficacy of novel disease-related therapeutics. Let’s all help raise global awareness of the physical, emotional and economic impact that lupus can have and bring greater attention and resources to efforts to end lupus. #makelupusvisible, #worldlupusday, #CRO, #mousediseasemodel, #IL23, #SLE, #drugtesting, #autoimmunity, #guselkumab, #tremfya, #TghIL23A, #humanized

Today is #RareDiseaseDay, dedicated to raising awareness and generating change for the 300 million people worldwide living with a rare disease, their families and caretakers. At ARMGO, we are committed to making a difference for rare disease patients by developing our proprietary Rycal® drugs. Rycals are novel small molecule therapeutics that repair leaky ryanodine receptor (RyR) channel proteins. These drugs have the potential to become a powerful new treatment option for patients suffering from Catecholaminergic Polymorphic Ventricular Tachycardia (#CPVT), a rare, genetic #arrhythmia and RYR1-related myopathy (RYR1-RM), a rare muscle disease. To find out more about Rare Disease Day, visit: https://lnkd.in/gk6hbAF. #RareDiseaseDay #CPVT #RYR1-RM #RYR-1Foundation

On World Microbiome Day, we celebrate how our understanding of the microbiome can impact our lives, and particularly the transformative potential of novel microbiome therapeutics. This year, we are on track for two of our live biotherapeutic products to enter human clinical trials in areas of high unmet patient need:- MB097 in #melanoma and MB310 in #ulcerativecolitis. Our cutting-edge microbiome profiling platform and “patient-first” discovery approach pinpoints precise bacterial strains linked to improved clinical response rates to help us develop therapeutics that can improve outcomes for patients. #pharma #biotech #research #bacteria #gutmicrobiome #oncology #microbiome

💡 Kinetiq Therapeutics won a $295,923 award from the Department of Health and Human Services' National Institutes of Health! 🎉 This award is part of the Small Business Innovation Research (SBIR) program, which aims to support innovative research and development projects that have the potential for commercialization. Kinetiq Therapeutics' project focuses on developing a subcutaneous enzyme therapy for Fabry disease, a rare genetic disorder that affects the body's ability to break down certain fatty substances. 🌟 The award is for a Phase I project, which will last for 12 months, starting from July 1, 2024, and ending on June 30, 2025. The goal of this project is to demonstrate the feasibility of Kinetiq Therapeutics' approach, which could potentially transform the current standard of care for Fabry disease and other lysosomal diseases. #SBIR #STTR #KinetiqTherapeutics #FabryDisease #RareDisease #Innovation

🔔 First clinical evaluation of an inhaled mRNA-based therapy designed to restore ciliary function in people with PCD ! 👏 ReCode Therapeutics’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) delivery platform was used to develop RCT1100, an inhaled mRNA therapy designed to deliver and express DNAI1 mRNA in target cells. 🔎 Interested in monitoring mRNA therapeutic related IP like recently published patent related to SORT LNP? Take advantage of KnowMade's patent monitoring service that is focused on therapeutic mRNA https://lnkd.in/eCfnR-ct #mrna #LNP #patent #innovation

Today LIVE in 1 hour: Lead investor Andreessen Horowitz (a16z) Bio + Health team in Arda Therapeutics joins us today for Family Office Insights Mercury Series Webinar featuring Adam Freund of Arda Therapeutics. Today: June 10 2024, 02:15 PM Eastern Time : RSVP: https://lnkd.in/gNyhUPuh Cells are the functional units of life. They are also the functional units of disease: many chronic diseases are caused by certain cell populations becoming too abundant or active. For example, subsets of stromal cells drives fibrosis, while the hyperactivity of particular immune cells leads to chronic inflammation. Arda Therapeutics is developing medicines to precisely remove these pathogenic cells, thereby treating diseases more effectively than by blocking individual proteins or signaling pathways. Their proprietary, single-cell-based discovery engine identifies pathogenic cells and specific markers to target them. They then design therapies to eliminate these - and only these - cells.

📣ISCT 2024 is right around the corner, and we’d love to see you there! Looking to drive up batch productivity and drive down manufacturing COGS? Don’t miss our two presentations: ✔Poster Presentation: Evaluation of Small Molecule Antagonists of Cellular Innate Immunity for Efficient Manufacturing of T-cell Therapeutics. ✔Oral Presentation: Harnessing the Power of High-Throughput Virology and Design of Experiment for Rapid Vector Production Process Optimization. (9:15-10:15 PT, Friday, May 31st, 2024) 💡 Learn how we leverage the power of Viral Sensitizers (VSEs), high-throughput virology, and Design of Experiments (DoE) to rapidly optimize viral vector production and boost viral yields. 🤝 Connect with us to learn more: https://lnkd.in/gGXmj5Gu #innovation #biomanufacturing #ISCT2024

ELRIG UK Drug Discovery 2024 is only a week away!   Nicholas Clare, Malek Haddad, Haris Choudhery and CEO, Chris Kirton will be attending and ready to showcase our cutting-edge iPSC-derived disease models and screening services. Celine Gomez will also be in attendance and presenting our poster: iPSC-derived hepatocytes as a novel platform for modelling Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) in vitro. So, whether you are looking for efficacy screening services, looking to predict hepatic safety, or in need of an iPSC-derived disease model to study #MASLD, #A1ATD, UTC disorders, Wilson’s disease or PFIC2, we have you covered.   Swing by our booth, D24, and check out Poster (no. 219), to discuss how our #CRISPR-edited disease models and in vitro screening platforms can de-risk your therapeutic research.   #DrugDiscovery #iPSC #CRISPR #Biotech #ELRIGDD24 #hepatocytes #liver #liverdisease #DefiniGEN